These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36336911)

  • 1. Alternative pathway amplification and infections.
    Shaughnessy J; Chabeda A; Lewis LA; Ram S
    Immunol Rev; 2023 Jan; 313(1):162-180. PubMed ID: 36336911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Properdin Pattern Recognition on Proximal Tubular Cells Is Heparan Sulfate/Syndecan-1 but Not C3b Dependent and Can Be Blocked by Tick Protein Salp20.
    Lammerts RGM; Talsma DT; Dam WA; Daha MR; Seelen MAJ; Berger SP; van den Born J
    Front Immunol; 2020; 11():1643. PubMed ID: 32849563
    [No Abstract]   [Full Text] [Related]  

  • 3. Linkage specificity and role of properdin in activation of the alternative complement pathway by fungal glycans.
    Agarwal S; Specht CA; Haibin H; Ostroff GR; Ram S; Rice PA; Levitz SM
    mBio; 2011; 2(5):. PubMed ID: 21878570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
    Farries TC; Lachmann PJ; Harrison RA
    Biochem J; 1988 May; 252(1):47-54. PubMed ID: 3421908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Properdin in C5 Convertase Activity and C5b-9 Formation in the Complement Alternative Pathway.
    Michels MAHM; Maas RJF; van der Velden TJAM; van de Kar NCAJ; van den Heuvel LPWJ; Volokhina EB;
    J Immunol; 2021 Nov; 207(10):2465-2472. PubMed ID: 34635587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is generation of C3(H
    Ekdahl KN; Mohlin C; Adler A; Åman A; Manivel VA; Sandholm K; Huber-Lang M; Fromell K; Nilsson B
    Mol Immunol; 2019 Oct; 114():353-361. PubMed ID: 31446306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.
    Newman SL; Mikus LK
    J Exp Med; 1985 Jun; 161(6):1414-31. PubMed ID: 2409200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assembly and regulation of the complement amplification loop in blood: the role of C3b-C3b-IgG complexes.
    Jelezarova E; Lutz HU
    Mol Immunol; 1999; 36(13-14):837-42. PubMed ID: 10698337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?
    Harrison RA
    Semin Immunopathol; 2018 Jan; 40(1):15-35. PubMed ID: 29167939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of C3b(2)--IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification.
    Jelezarova E; Vogt A; Lutz HU
    Biochem J; 2000 Jul; 349(Pt 1):217-23. PubMed ID: 10861231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation.
    Xu W; Berger SP; Trouw LA; de Boer HC; Schlagwein N; Mutsaers C; Daha MR; van Kooten C
    J Immunol; 2008 Jun; 180(11):7613-21. PubMed ID: 18490764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The alternative pathway of complement.
    Pangburn MK; Müller-Eberhard HJ
    Springer Semin Immunopathol; 1984; 7(2-3):163-92. PubMed ID: 6238433
    [No Abstract]   [Full Text] [Related]  

  • 13. Factor H-related protein 4 activates complement by serving as a platform for the assembly of alternative pathway C3 convertase via its interaction with C3b protein.
    Hebecker M; Józsi M
    J Biol Chem; 2012 Jun; 287(23):19528-36. PubMed ID: 22518841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the function of activated properdin by squid chondroitin sulfate E glycosaminoglycan and murine bone marrow-derived mast cell chondroitin sulfate E proteoglycan.
    Wilson JG; Fearon DT; Stevens RL; Seno N; Austen KF
    J Immunol; 1984 Jun; 132(6):3058-63. PubMed ID: 6427331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin.
    Alcorlo M; Tortajada A; Rodríguez de Córdoba S; Llorca O
    Proc Natl Acad Sci U S A; 2013 Aug; 110(33):13504-9. PubMed ID: 23901101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Properdin in Killing of Non-Pathogenic
    Martinez APG; Abreu PAE; de Arruda Vasconcellos S; Ho PL; Ferreira VP; Saggu G; Barbosa AS; Isaac L
    Front Immunol; 2020; 11():572562. PubMed ID: 33240263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
    Mayes JT; Schreiber RD; Cooper NR
    J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the alternative complement pathway.
    Fearon DT
    CRC Crit Rev Immunol; 1979 Nov; 1(1):1-32. PubMed ID: 162484
    [No Abstract]   [Full Text] [Related]  

  • 19. Activation of the alternative pathway of human complement by autologous cells expressing transmembrane recombinant properdin.
    Vuagnat BB; Mach J; Le Doussal JM
    Mol Immunol; 2000 Jun; 37(8):467-78. PubMed ID: 11090881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.
    Farries TC; Lachmann PJ; Harrison RA
    Biochem J; 1988 Aug; 253(3):667-75. PubMed ID: 3140783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.